<DOC>
	<DOC>NCT02770131</DOC>
	<brief_summary>Review of clinical characteristics of patients who are prescribed Repatha® and how their treatment is managed.</brief_summary>
	<brief_title>Chart Review of Repatha® in Subjects With Hyperlipidaemia</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipidemias</mesh_term>
	<criteria>Adults (&gt;18 years) Provided informed consent Initiated on Repatha® at physician's discretion, after 1st August 2015 Received at least one dose of Repatha® Enrolled in an interventional study of PCSK9 inhibitor within 12 weeks prior to initiation of Repatha®</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>hypercholesterolaemia</keyword>
	<keyword>lipid-lowering therapies</keyword>
</DOC>